Header

UZH-Logo

Maintenance Infos

Brief report: cobicistat compared with ritonavir as a pharmacoenhancer for atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate: week 144 results


Gallant, Joel E; Koenig, Ellen; Andrade-Villanueva, Jaime; Chetchotisakd, Ploenchan; DeJesus, Edwin; Antunes, Francisco; Arastéh, Keikawus; Rizzardini, Giuliano; Fehr, Jan; Liu, Hui C; Abram, Michael E; Cao, Huyen; Szwarcberg, Javier (2015). Brief report: cobicistat compared with ritonavir as a pharmacoenhancer for atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate: week 144 results. Journal of Acquired Immune Deficiency Syndromes, 69(3):338-340.

Abstract

BACKGROUND: Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity.
METHODS: International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144.
RESULTS: At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48.
CONCLUSIONS: Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.

Abstract

BACKGROUND: Cobicistat (COBI) is a pharmacoenhancer with no antiretroviral activity.
METHODS: International, randomized double-blind active-controlled trial to evaluate the efficacy and safety of COBI vs ritonavir (RTV) as a pharmacoenhancer of atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate in HIV treatment-naive patients followed through week 144.
RESULTS: At Week 144, virologic suppression was achieved in 72% (COBI) and 74% (RTV) of patients. Adverse events leading to study drug discontinuation occurred in 11% of patients in each group. Median changes in serum creatinine (mg/dL) were +0.13 (COBI) and +0.07 (RTV) and were unchanged from week 48.
CONCLUSIONS: Once-daily COBI is a safe and effective pharmacoenhancer of the protease inhibitor atazanavir.

Statistics

Citations

16 citations in Web of Science®
16 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

16 downloads since deposited on 17 Nov 2015
12 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Infectious Diseases
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:1 July 2015
Deposited On:17 Nov 2015 10:06
Last Modified:28 Oct 2016 07:45
Publisher:Lippincott Williams & Wilkins
ISSN:1525-4135
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1097/QAI.0000000000000598
PubMed ID:26181707

Download

Download PDF  'Brief report: cobicistat compared with ritonavir as a pharmacoenhancer for atazanavir in combination with emtricitabine/tenofovir disoproxil fumarate: week 144 results'.
Preview
Content: Published Version
Filetype: PDF
Size: 145kB
View at publisher